Due to their superior potency over traditional cytotoxic chemotherapy, TKIs overcome some novel challenges in the therapeutic paradigm of EGFR‐mutant NSCLC, such as slow progression or oligo PD.23 This evidence concerns the gene EGFR and non-small cell lung carcinoma.